| Endometrial cancer morphologya | |||||||
---|---|---|---|---|---|---|---|---|
 | Endometrioid carcinomab | Serous or clear cellc | Carcinosarcomad | Sarcomae | ||||
 | N = 1,580 | N = 108 | N = 108 | N = 54 | ||||
Age at diagnosis of endometrial cancer (years) | ||||||||
   < 55 | 165 | 10.4 | 4 | 3.7 | 8 | 7.4 | 12 | 22.2 |
   55 to 64 | 413 | 26.1 | 19 | 17.6 | 17 | 15.7 | 15 | 27.8 |
   65 to 74 | 553 | 35.0 | 39 | 36.1 | 39 | 36.1 | 17 | 31.5 |
   75 to 84 | 363 | 23.0 | 34 | 31.5 | 33 | 30.6 | 9 | 16.7 |
   85 and over | 86 | 5.4 | 12 | 11.1 | 11 | 10.2 | 1 | 1.9 |
   Mean (SD), years | 68.9 (10.3) | 73.4 (9.4) | 71.2 (10.4) | 67.6 (9.5) | ||||
 | analysis of variance (3 d.f.): P < 0.001f | |||||||
Tamoxifen use | Â | Â | Â | Â | Â | Â | Â | Â |
   Not used | 651 | 41.2 | 44 | 40.7 | 19 | 17.6 | 17 | 31.5 |
   Used | 929 | 58.8 | 64 | 59.3 | 89 | 82.4 | 37 | 68.5 |
 | Pearson chi-sq (3 d.f.): P < 0.0001g | |||||||
   Duration of tamoxifen use among users | ||||||||
Used, < 2 years | 272 | 29.3 | 19 | 29.7 | 11 | 12.4 | 10 | 27.0 |
2 to < 5 years | 326 | 35.1 | 19 | 29.7 | 31 | 34.8 | 12 | 32.4 |
5 or more years | 285 | 30.7 | 23 | 35.9 | 37 | 41.6 | 13 | 35.1 |
Used, duration unknown | 46 | 5.0 | 3 | 4.7 | 10 | 11.2 | 2 | 5.4 |
Mean (SD), years | 4.1 (3.2) | 4.1 (2.8) | 5.2 (3.3) | 4.0 (2.8) | ||||
 | analysis of variance (3 d.f.): P = 0.025g | |||||||
   Tamoxifen, time since last use among users | ||||||||
Still on/≤ 3 months | 649 | 69.9 | 34 | 53.1 | 50 | 56.2 | 24 | 64.9 |
3 months to < 1 year | 70 | 7.5 | 5 | 7.8 | 5 | 5.6 | 3 | 8.1 |
1 year to < 3 years | 73 | 7.9 | 8 | 12.5 | 10 | 11.2 | 6 | 16.2 |
3 years to < 5 years | 35 | 3.8 | 6 | 9.4 | 7 | 7.9 | 2 | 5.4 |
5 or more years | 56 | 6.0 | 8 | 12.5 | 8 | 9.0 | 0 | 0.0 |
Used, time unknown | 46 | 5.0 | 3 | 4.7 | 9 | 10.1 | 2 | 5.1 |
Mean (SD), years | 0.8 (2.0) | 1.7 (2.8) | 1.3 (2.2) | 0.7 (1.3) | ||||
 | analysis of variance (3 d.f.): P = 0.002g | |||||||
FIGO stage | Â | Â | Â | Â | Â | Â | Â | Â |
   I | 914 | 57.9 | 46 | 42.6 | 35 | 32.4 | 21 | 38.9 |
   II | 111 | 7.0 | 14 | 13.0 | 3 | 2.8 | 4 | 7.4 |
   III/IV | 82 | 5.2 | 27 | 25.0 | 20 | 18.5 | 11 | 20.4 |
   Unknown | 473 | 29.9 | 21 | 19.4 | 50 | 46.3 | 18 | 33.3 |
 | Peasron chi-sq (9 d.f.): P < 0.001g | |||||||
Interval between breast and endometrial cancer (years) | ||||||||
   3 to 12 months | 102 | 6.5 | 8 | 7.4 | 3 | 2.8 | 2 | 3.7 |
   1 to < 3 years | 400 | 25.3 | 17 | 15.7 | 16 | 14.8 | 15 | 27.8 |
   3 to < 5 years | 305 | 19.3 | 18 | 16.7 | 18 | 16.7 | 12 | 22.2 |
   5 to < 10 years | 508 | 32.2 | 47 | 43.5 | 46 | 45.4 | 21 | 38.9 |
   10 to 29 years | 265 | 16.8 | 18 | 16.7 | 22 | 20.4 | 4 | 7.4 |
   Mean (SD), years | 5.9 (4.3) | 6.5 (4.1) | 6.9 (3.9) | 5.2 (3.2) | ||||
 | analysis of variance (3 d.f.): (P = 0.039)g | |||||||
Total | 1,580 | 100.0 | 108 | 100.0 | 108 | 100.0 | 54 | 100.0 |